Epigenetic Therapy Targets Endocrine-Resistant Breast Cancer

被引：0
|
作者：
机构：
来源：
Genetic Engineering and Biotechnology News | 2024年 / 44卷 / 04期
关键词：
D O I：
10.1089/gen.44.04.12
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
相关论文
共 50 条
  • [31] Revisiting Estrogen for the Treatment of Endocrine-Resistant Breast Cancer: Novel Therapeutic Approaches
    Shete, Nivida
    Calabrese, Jordan
    Tonetti, Debra A.
    CANCERS, 2023, 15 (14)
  • [32] Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer
    Jing Chen
    Runlan Wan
    Qinqin Li
    Zhenghuan Rao
    Yanlin Wang
    Lei Zhang
    Alexander Tobias Teichmann
    Cancer Cell International, 21
  • [33] MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells
    Petri, Belinda J.
    Piell, Kellianne M.
    Wilt, Ali E.
    Howser, Alexa D.
    Winkler, Laura
    Whitworth, Mattie R.
    Valdes, Bailey L.
    Lehman, Norman L.
    Clem, Brian F.
    Klinge, Carolyn M.
    ENDOCRINE-RELATED CANCER, 2023, 30 (11)
  • [34] Genes Regulated by miRNA in Endocrine-Resistant Breast Tumours
    Larionov, A.
    Faratian, D.
    Caldwell, H.
    Sims, A.
    Fawkes, A.
    Murphy, L.
    Renshaw, L.
    Dixon, J. M.
    CANCER RESEARCH, 2009, 69 (24) : 815S - 815S
  • [35] miRNA Profiling of Endocrine-Resistant Breast Tumours.
    Larionov, A.
    Faratian, D.
    Caldwell, H.
    Sims, A.
    Fawkes, A.
    Murphy, L.
    Renshaw, L.
    Dixon, J. M.
    CANCER RESEARCH, 2009, 69 (24) : 809S - 809S
  • [36] Epigenetic derepression converts PPARγ into a druggable target in triple-negative and endocrine-resistant breast cancers
    Loo, Ser Yue
    Syn, Nicholas L.
    Koh, Angele Pei-Fern
    Teng, Janet Cheng-Fei
    Deivasigamani, Amudha
    Tan, Tuan Zea
    Thike, Aye Aye
    Vali, Shireen
    Kapoor, Shweta
    Wang, Xiaoyuan
    Wang, Jiong Wei
    Tan, Puay Hoon
    Yip, George W.
    Sethi, Gautam
    Huang, Ruby Yun-Ju
    Hui, Kam Man
    Wang, Lingzhi
    Goh, Boon Cher
    Kumar, Alan Prem
    CELL DEATH DISCOVERY, 2021, 7 (01)
  • [37] A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer
    Trinh, X. B.
    Sas, L.
    Van Laere, S. J.
    Prove, A.
    Deleu, I.
    Rasschaert, M. A.
    Van de Velde, H.
    Vinken, P.
    Vermeulen, P. B.
    van Dam, P. A.
    Wojtasik, A.
    De Mesmaeker, P.
    Tjalma, W. A.
    Dirix, L. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer
    Trinh, X. B.
    Sas, L.
    Van Laere, S. J.
    Prove, A.
    Deleu, I.
    Rasschaert, M.
    Van De Velde, H.
    Vinken, P.
    Vermeulen, P. B.
    Van Dam, P. A.
    Wojtasik, A.
    De Mesmaeker, P.
    Tjalma, W. A.
    Dirix, L. Y.
    ONCOLOGY REPORTS, 2012, 27 (03) : 657 - 663
  • [39] Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells
    Chan, J. Y.
    LaPara, K.
    Yee, D.
    ONCOGENE, 2016, 35 (32) : 4235 - 4243
  • [40] Native top-down proteomics enables discovery in endocrine-resistant breast cancer
    Gomes, Fabio P.
    Durbin, Kenneth R.
    Schauer, Kevin
    Nwachukwu, Jerome C.
    R. Kobylski, Robin
    Njeri, Jacqline W.
    Seath, Ciaran P.
    Saviola, Anthony J.
    McClatchy, Daniel B.
    Diedrich, Jolene K.
    Garrett, Patrick T.
    Papa, Alexandra B.
    Ciolacu, Ianis
    Kelleher, Neil L.
    Nettles, Kendall W.
    Yates III, John R.
    NATURE CHEMICAL BIOLOGY, 2025,
12345